Other common alterations in gliomas are TP53 mutations and Cyclin Dependent Kinase Inhibitor 2A and B (CDKN2A/B) copy number losses, which show high frequencies in lower and higher grade gliomas, respectively [19]. This evidence concerns the gene TP53 and central nervous system cancer.